We are live on ! Find out more
SMMT icon

Summit Therapeutics
SMMT

15 hedge funds and large institutions have $35.8M invested in Summit Therapeutics in 2017 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

55% more capital invested

Capital invested by funds: $23.1M → $35.8M (+$12.7M)

36% more funds holding

Funds holding: 11 → 15 (+4)

0.01% less ownership

Funds ownership: 4.36% → 4.35% (-0.01%)

25% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 4

Holders
15
Holders Change
+4
Holders Change %
+36.36%
% of All Funds
0.37%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
4
Increased
3
Reduced
4
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
KCM
Knoll Capital Management
Florida
+$1.16M
2
Renaissance Technologies
Renaissance Technologies
New York
+$232K
3
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$149K
4
Morgan Stanley
Morgan Stanley
New York
+$31.5K
5
State of Tennessee, Department of Treasury
State of Tennessee, Department of Treasury
Tennessee
+$25.8K

Top Sellers

Rank Fund Capital Flow
1
Point72 Asset Management
Point72 Asset Management
Connecticut
-$1.45M
2
Millennium Management
Millennium Management
New York
-$163K
3
UBS Group
UBS Group
Switzerland
-$12.7K
4
First Eagle Investment Management
First Eagle Investment Management
New York
-$1.16K
Name Holding Trade Value Shares
Change 		Change in
Stake
LPU
1
Lansdowne Partners (UK)
United Kingdom
$12.3M – – –
Point72 Asset Management
2
Point72 Asset Management
Connecticut
$10.6M -$1.45M -124,968 -13%
Axa
3
Axa
France
$3.9M +$763 +66 +0%
First Eagle Investment Management
4
First Eagle Investment Management
New York
$2.33M -$1.16K -100 -0.1%
SFM
5
Sphera Funds Management
Israel
$1.97M – – –
GPCM
6
Granite Point Capital Management
Massachusetts
$1.56M – – –
KCM
7
Knoll Capital Management
Florida
$1.33M +$1.16M +100,000 New
Millennium Management
8
Millennium Management
New York
$1.08M -$163K -14,079 -15%
Renaissance Technologies
9
Renaissance Technologies
New York
$267K +$232K +20,102 New
Acadian Asset Management
10
Acadian Asset Management
Massachusetts
$171K +$149K +12,850 New
Morgan Stanley
11
Morgan Stanley
New York
$89K +$31.5K +2,721 +68%
Deutsche Bank
12
Deutsche Bank
Germany
$67K +$18.1K +1,568 +43%
State of Tennessee, Department of Treasury
13
State of Tennessee, Department of Treasury
Tennessee
$30K +$25.8K +2,234 New
Wells Fargo
14
Wells Fargo
California
$16K – – –
UBS Group
15
UBS Group
Switzerland
$9K -$12.7K -1,100 -61%

SMMT Hedge Fund Activity: Q1 2017 in Review

15 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Summit Therapeutics (SMMT) for Q1 2017, worth a combined $35.8M — up 55% from $23.1M a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new SMMT positions and 0 closed out — a net gain of 4 holders — while 3 added to existing stakes and 4 trimmed.

The largest buyer was Knoll Capital Management, opening a new position worth an estimated $1.16M. The largest seller was Point72 Asset Management, cutting an estimated $1.45M.

  • 15 institutional investors held Summit Therapeutics (SMMT) as of Q1 2017, up from 11 in Q4 2016.
  • Funds reported $35.8M of Summit Therapeutics stock for Q1 2017, up 55% quarter-over-quarter.
  • 4 funds opened new Summit Therapeutics positions in Q1 2017 and 0 closed out, a net change of +4 holders.
  • The largest Summit Therapeutics buyer in Q1 2017 was Knoll Capital Management, an estimated $1.16M added.
  • The largest Summit Therapeutics seller in Q1 2017 was Point72 Asset Management, an estimated $1.45M sold.

Based on aggregated 13F filings for Q1 2017.